DIC
KYMR icon

Deer IX & Co’s Kymera Therapeutics KYMR Stock Holding History

Deer IX & Co’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$36.2M Sell
615,895
-619,413
-50% -$35.9M 3.72% 5
2021
Q2 		$59.9M Sell
1,235,308
-425,163
-26% -$18.5M 5.42% 2
2021
Q1 		$64.5M Sell
1,660,471
-94,885
-5% -$5.71M 55.32% 1
2020
Q4 		$97.9M Buy
+1,755,356
New +$85.6M 48.97% 2

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Deer IX & Co's KYMR Position: Q3 2021 in Review

Deer IX & Co reduced its Kymera Therapeutics (KYMR) stake by 50% in Q3 2021, selling an estimated $35.9M and leaving 615,895 shares worth $36.2M. The position accounts for 3.72% of the portfolio, ranked #5.

Deer IX & Co first reported a position in KYMR in Q4 2020 and has held it in 4 quarters since. The position peaked at $97.9M in Q4 2020. 115 funds tracked by Wall St. Rank hold KYMR as of Q3 2021.

  • Deer IX & Co held 615,895 shares of Kymera Therapeutics worth $36.2M as of Q3 2021.
  • Deer IX & Co sold 619,413 Kymera Therapeutics shares in Q3 2021, an estimated $35.9M.
  • Kymera Therapeutics made up 3.72% of Deer IX & Co's portfolio in Q3 2021, its #5 holding.
  • Deer IX & Co first reported a position in Kymera Therapeutics in Q4 2020 and has held it in 4 quarters since.
  • Deer IX & Co's Kymera Therapeutics position peaked at $97.9M in Q4 2020.
  • 115 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2021.

Based on Deer IX & Co's 13F filing for Q3 2021, filed 15 Nov 2021.